Which weight-loss medication class should be avoided in patients with hypertension or heart disease?

• A. Sympathomimetics (phentermine/diethylpropion)
• B. Orlistat
• C. GLP-1 receptor agonists
• D. Lorcaserin

Answer: (A)

Stimulant weight‑loss meds that activate the sympathetic nervous system can raise blood pressure and heart rate, increasing workload on the heart and the risk of angina, arrhythmias, or other cardiovascular events. Because of this, they are avoided in patients with hypertension or heart disease. Phentermine and diethylpropion are classic examples; they boost norepinephrine activity and sympathetic drive, which directly elevates BP and HR and can worsen underlying heart conditions.

Other weight‑loss options work differently and don’t carry the same cardiovascular stimulant effects. Orlistat acts in the gut to block fat absorption with mostly GI side effects and minimal impact on blood pressure. GLP‑1 receptor agonists promote weight loss and can even have favorable cardiovascular effects, sometimes lowering blood pressure. Lorcaserin reduces appetite through serotonin pathways and doesn’t rely on sympathetic stimulation, though it has its own safety considerations. The key idea is that the stimulant class poses the greatest cardiovascular risk for someone with hypertension or heart disease, so it’s the one to avoid.